Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of where AI can be leveraged in biopharma.
A monthly injectable GLP-1 drug from Pfizer’s $10 billion Metsera acquisition is now on track for a Phase 3 program spanning 10 pivotal studies this year. While Pfizer’s pipeline spans internally developed and in-licensed assets for other targets, the pharma company says the Metsera drug is the foundation for its obesity strategy pursuing monotherapies and combination treatments.
How to turn analytics into actual policy outcomes.
Alveus Therapeutics’ Phase 2-ready lead drug hits the same two targets as Amgen’s MariTide, but with the potential for a dosing advantage. The startup’s pipeline also includes molecules that could compete with drugs in development by Roche and Novo Nordisk.
The Peterson Health Technology Institute outlined five key recommendations for employers seeking to design sustainable GLP-1 coverage.
The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription drug costs overall.
Eli Lilly’s LillyDirect platform is partnering with Walmart to let patients pick up prescriptions for its GLP-1 drug Zepbound at Walmart pharmacies, expanding access beyond home delivery.
Arbiter’s Anjali Jameson on hospital and payer alignment.
Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash.
Withings Health Solutions added Ilant Health to its Obesity Care Network and shared best practices to improve patient monitoring, engagement and outcomes.
Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for treating obesity.
Response Pharmaceuticals takes a new approach to weight loss with an oral small molecule designed to inhibit a protein called iMTP to reduce uptake of fats and cholesterol. While this drug’s lead indication is addressing weight gain in patients taking antipsychotics, the company is also exploring other metabolic indications such as patients who need a post-GLP-1 therapy.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
GLP-1s have proven to be highly effective for weight loss but pose significant cost challenges for employers, according to a recent panel of experts at MedCity INVEST.
WeightWatchers recently filed for bankruptcy. Part of the reason is because it couldn't adapt fast enough to a rapidly changing weight-loss environment spurred by the rising popularity of GLP-1s, experts said.
Eli Lilly reported that in addition to achieving greater reductions in weight, Zepbound-treated patients achieved greater reductions in waist circumference compared to those treated with Novo Nordisk’s Wegovy. Full details from the head-to-head Phase 3 test were presented at the European Congress on Obesity meeting.
Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform.
The annual growth rate of spending for traditional drugs increased from 2.1% in 2021 to 12.8% in 2024, according to Evernorth Research Institute.